Moderna and Merck & Co. have developed a cancer vaccine that cuts the risk of death or recurrence of most deadly skin cancer by 44 percent compared to Merck's Keytruda on its own, according to researchers.
Federal health advisers voted overwhelmingly against an experimental treatment for Lou Gehrig’s disease at a Wednesday meeting prompted by years of patient efforts seeking access to the unproven therapy.
